1. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of mul-
tidrug-resistant gram-positive bacterial infections. J Med Chem 1996; 39: 673-679.
2. Yuan S, Shen DD, Bai YR, et al. Oxazolidinone: A promising scaffold for the development of antibacterial drugs. Eur J Med Chem 2023; 250: 115239.
3. Champney WS, Miller M. Linezolid is a specific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells. Curr Microbiol 2002; 44: 350-356
4. Katahira EJ, Davidson SM, Stevens DL, Bolz DD. Subinhibitory concentrations of tedizolid potently inhibit extracellular toxin production by methicillin-sensitive and methicillin-resistant
Staphylococcus aureus. J Med Microbiol 2019; 68(2): 255-262.
5. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-142.
6. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveil-
lance Program. Antimicrob Agents Chemother 2007; 51(4): 1491-1493.
7. Curtis G. Gemmell, on behalf of participating investigators in France, Germany, Holland, Spain, Italy, Sweden and the UK. Susceptibility of a variety of clinical isolates to linezolid: a European
inter-country comparison. J Antimicrob Chemother 2001; 48: 47–52.
8. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJC. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials
against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003; 47: 2334–2338.
9. Schlaberg R, Fisher MA, Hanson KE. Susceptibility profiles of Nocardia isolates based on current taxonomy. Antimicrob Agents Chemother 2014; 58(2): 795-800.
10. Tan YE, Chen SC, Halliday CL. Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: Results from a large tertiary laboratory in Australia. J Glob
Antimicrob Resist 2020; 20: 110-117.
11. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 2005; 56(2): 407-9.
12. Zong Z, Jing W, Shi J, et al. Comparison of In Vitro Activity and MIC Distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively
drug-resistant Mycobacterium tuberculosis in China. Antimicrob Agents Chemother 2018; 62(8): e00165-18.
13. Zhao W, Jiang Y, Bao P, at al. Evaluation of the efficacy of novel oxazolidinone analogues against nontuberculous mycobacteria in vitro. Jpn J Infect Dis 2015; 68(6): 520-2.
14. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012; 56: 603–612.
15. Schwarz S, Zhang W, Du XD, et al. Mobile oxazolidinone resistance genes in Gram-positive and Gram-negative bacteria. Clin Microbiol Rev 2021; 34(3): e0018820.
16. Wang Y, Lv Y, Cai J, et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of
human and animal origin. J Antimicrob Chemother 2015; 70: 2182–2190.
17. Antonelli A, D’Andrea MM, Brenciani A, et al. Characterization of poxtA, a novel phenicol–oxazolidinone–tetracycline resistance gene from an MRSA of clinical origin. J Antimicrob Che-
mother 2018; 73: 1763–1769.
18. Mendes RE, Deshpande L, Streit JM, et al. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J
Antimicrob Chemother 2018; 73(7): 1880-1887.
19. Kempf M, Arhin FF, Kuraieva A, Utt E. In vitro activity of ceftaroline against isolates of Gram-positive bacteria from patients with bloodstream infections collected as a part of ATLAS between
2017 and 2020. Infect Drug Resist 2024; 17: 343-354.
20. Carvalhaes CG, Sader HS, Flamm RK, Streit JM, Mendes RE. Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive
infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. Antimicrob Agents Chemother 2020; 64(4):
e00175-20.
21. ZYVOX(R) Intravenous Injection [Package Insert] Pfizer Inc.; New York, NY, USA: 2023.
22. Hosmann A, Moser MM, van Os W, et al. Linezolid brain penetration in neurointensive care patients. J Antimicrob Chemother 2024; 79: 669-677.
23. Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet 2018; 57: 559-575.
24. Heidari S, Khalili H. Linezolid pharmacokinetics: a systematic review for the best clinical practice. Eur J Clin Pharmacol 2023; 79: 195-206.
25. Hui LA, Bodolea C, Vlase L, Hiriscau EI, Popa A. Linezolid administration to critically ill patients: Intermittent or continuous infusion? A systematic literature search and review. Antibiotics
(Basel) 2022; 11: 436.
26. Feng J, Xiang F, Cheng J, Gou Y, Li J. Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and
soft tissue infections: An updated network meta-analysis. Infect Dis Ther 2021; 10: 1531–1547.
27. Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist 2021; 24:
98-105.
28. Kawasuji H, Nagaoka K, Tsuji Y, et al. Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: A
systematic review and meta-analysis. Antibiotics (Basel) 2023; 12: 697.
29. Veerman K, Goosen J, Spijkers K, Jager N, Heesterbeek P, Telgt D. Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects. J Antimicrob Chemother
2023; 78: 2660-2666.
30. Theil C, Schmidt-Braekling T, Gosheger G, et al. Clinical use of linezolid in periprosthetic joint infections – a systematic review. J Bone Jt Infect 2020; 6: 7-16.
31. Sipahi OR, Bardak-Ozcem S, Turhan T, et al. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt) 2013; 14: 357-362.
32. Pries-Heje MM, Hjulmand JG, Lenz IT, et al. Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study. Eur Heart J 2023; 44: 5095-5106.
33. Britt NS, Potter EM, Patel N, Steed ME. Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant Enterococcus faecium bacte-
remia. Antimicrob Agents Chemother 2017; 61: e02216-16.
34. Lopez-Luis BA, Ponce-De-León A, Ortiz-Brizuela E, et al. Risk factors associated with failure of linezolid therapy in vancomycin-resistant Enterococcus faecium bacteremia: A retrospective
cohort study in a referral center in Mexico. Microb Drug Resist 2022; 28: 744-749.
35. Delgado V, Ajmone Marsan N, de Waha S, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J 2023; 44: 3948-4042.
36. Wingler MJ, Patel NR, King ST, Wagner JL, Barber KE, Stover KR. Linezolid for the treatment of urinary tract infections caused by vancomycin-resistant Enterococci. Pharmacy (Basel) 2021;
9: 175.
37. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T; Linezolid Community-Acquired Pneumonia Study Group. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the
treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-728.
38. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41: 296-308.
39. Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019; 3: CD012836.
40. WHO consolidated guidelines on tuberculosis: Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update [Internet]. Geneva: World Health Organization; 2022.
41. Margalit I, Lebeaux D, Tishler O, et al. How do I manage nocardiosis? Clin Microbiol Infect 2021; 27: 550-558.
42. Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol
2024; 15: 1338902.
43. Santini A, Ronchi D, Garbellini M, Piga D, Protti A. Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes. Expert Opin Drug Saf 2017; 16: 833-843.
44. Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 2015; 11: 1849-1859.
45. Burdette SD, Trotman R. Tedizolid: The first once-daily oxazolidinone class antibiotic. Clin Infect Dis 2015; 61: 1315-1321.
46. Carvalhaes CG, Sader HS, Streit JM, Mendes RE. Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results
from the Surveillance of Tedizolid Activity and Resistance (STAR) programme. JAC Antimicrob Resist 2022; 4: dlac088.
47. Sivextro® (tedizolid) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc2023.
48. Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: A systematic review and meta-analysis. Antibiotics (Basel)
2019; 8: 137.
49. Wunderink RG, Roquilly A, Croce M, et al. A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated Gram-positive hospital-acqu-
ired or ventilator-associated bacterial pneumonia. Clin Infect Dis 2021; 73: e710-718.
50. Negatu DA, Aragaw WW, Cangialosi J, Dartois V, Dick T. Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections. Antimicrob Agents
Chemother 2023; 67: e0165522.